Metsera Inc.’s shares jumped after the obesity startup shared better-than-expected data on a weight-loss shot that would ...

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

Metsera (NASDAQ:MTSR) stock jumps 16% as Wall Street continues to cheer positive Phase 1 data for its weight loss drug ...

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

New York-based Metsera, a biopharma developing medicines for obesity and metabolic diseases, closed Monday’s trading nearly ...

Metsera's MET-233i shows sustained weight loss, long duration of action, and mild side effects in a Phase 1 trial, advancing its obesity treatment plans.

An experimental Metsera obesity drug led to an average 8.4% weight loss in a small clinical trial, preliminary results that keep the biotech competitive in the crowded mix of companies pursuing a ...

Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced ...

Metsera’s obesity drug candidate targeting the amylin hormone showed marked efficacy in an early trial, the company said ...

In what Guggenheim Partners called one of Metsera’s “critical program milestones” this year, its ultra-long-acting amylin ...

Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a ...